Stepan G. Pilyo

Stepan G. Pilyo

Auto-generated profile, based on publicly available information

Stepan G. Pilyo

V.P. Kukhar Institute of Bioorganic Chemistry and Petrochemistry of the NAS of Ukraine, Kyiv, Ukraine

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 September 2019 in Journal of Heterocyclic Chemistry
Verified
Journal Article
Closed access
PDF file
MKMaryna V. Kachaeva
Maryna V. Kachaeva
DHDiana M. Hodyna
Diana M. Hodyna
NONataliya V Obernikhina
Nataliya V Obernikhina
SPStepan G. Pilyo
Stepan G. Pilyo
YKYulia S. Kovalenko
Yulia S. Kovalenko
VBVolodymyr S. Brovarets
Volodymyr S. Brovarets

30 December 2020 in Ukrainica Bioorganica Acta
Verified
Journal Article
Open access
SPStepan Pilyo
Stepan Pilyo
ОKОlexandr Kozachenko
Оlexandr Kozachenko
VZVictor Zhirnov
Victor Zhirnov
MKMaryna Kachaeva
Maryna Kachaeva
OKOleksandr Kobzar
Oleksandr Kobzar
VBVolodymyr S. Brovarets
Volodymyr S. Brovarets
A series of new 2-aryl 5-sulfonyl-1,3-oxazole-4-carboxylates for NCI anticancer screening protocol against 60 cancer cell lines were synthesized. Screening was performed in vitro on 60 cell lines of lungs, kidneys, CNS, ovaries, prostate, and breast cancer, leukemia, and melanoma. Methyl 5-benzylsulfonyl-2-phenyl-1,3-oxazole-4-carboxylate 15 exhibited potent and broad range of cytotoxic activity against tested human cancer cells with average GI50, TGI, and LC50 values of 5.37·10-6, 1.29·10-5 and 3.6·10-5 mol/L respectively. Molecular docking was used to evaluate the possible interaction of compound 15 with tubulin as well as a complex formation with CDK2.

1 February 2022 in Russian Journal of General Chemistry
Verified
Journal Article
Open access
PDF file
OSOleksandr Severin
Oleksandr Severin
SPS. G. Pilyo
S. G. Pilyo
LPL. M. Potikha
L. M. Potikha
VBVolodymyr S. Brovarets
Volodymyr S. Brovarets
A method for the synthesis of 5-phenyl-1,3-thiazole-4-sulfonyl chloride was developed based on the cyclization of ethyl 2-{[1-(benzylsulfanyl)-2-oxo-2-phenylethyl]amino}-2-oxoacetate obtained from available reagents under the action of the Lawesson’s reagent and oxidative chlorination of the intermediate benzyl 5-phenyl-1,3thiazol-4-ylsulfide. The resulting sulfonyl chloride was converted into a series of 5-phenyl-1,3-thiazole-4-sulfonamide derivatives for which in vitro antitumor activity screening studies were performed on 60 cancer cell lines.

14 July 2021 in Current Organic Chemistry
Verified
Journal Article
Closed access
PDF file
EVEvgenia S. Velihina
Evgenia S. Velihina
NONataliya V Obernikhina
Nataliya V Obernikhina
SPStepan G. Pilyo
Stepan G. Pilyo
OKOleksiy D. Kachkovsky
Oleksiy D. Kachkovsky
VBVolodymyr S. Brovarets
Volodymyr S. Brovarets
Background: Synthesis of a series of 2-(dichloromethyl)pyrazolo[1,5- a][1,3,5]triazines was carried out and evaluated in vitro for their anticancer activity against a panel of 60 cell lines derived from nine cancer types. Methods: The joint quantum-chemical and experimental study of the influence of the extended πconjugated phenyl substituents on the electron structure of the pyrazolo[1,5- a][1,3,5]triazines as Pharmacophores were performed. It is shown that the decrease in the barriers to the rotation of phenyl substituents in compounds 1-7 possibly leads to an increase in the anti-cancer activity, which is in agreement with the change in the parameter biological affinity Φ0. Analysis of the S0 → S1 electronic transitions (π→π*) of the pyrazolo[1,5- a][1,3,5]triazines shows that an increase in their intensity correlates with anti-cancer activity. Results: Thus, the introduction of phenyl substituents increases the likelihood of investigated pyrazolo[1,5-a][1,3,5]triazines interacting with protein molecules (Biomolecule) by the π-stacking mechanism. In both methyl and phenyl derivatives of pyrazolo[1,5-a][1,3,5]triazines, the second electronic transition includes the n- MO (the level of the lone electron pair in two-coordinated nitrogen atoms). The highest intensity of the η→π* electronic transition is observed in pyrazolo[1,5-a][1,3,5]triazine with pyridine residue, which does not exhibit anticancer activity, but exhibits antiviral activity [13]. Conclusion: It can be assumed that the possibility of the formation of [Pharmacophore-Biomolecule] complex by hydrogen bonding ([H-B]) mechanism with protein molecules increases.

30 December 2023 in Ukrainica Bioorganica Acta
Verified
Journal Article
Open access
PDF file
ABAlona V. Beiko
Alona V. Beiko
OKOleksandr L. Kobzar
Oleksandr L. Kobzar
MKMaryna V. Kachaeva
Maryna V. Kachaeva
SPStepan G. Pilyo
Stepan G. Pilyo
OKOlexandr P. Kozachenko
Olexandr P. Kozachenko
AVAndriy I. Vovk
Andriy I. Vovk
A series of rhodanine derivatives bearing 4-(furan-2-yl)benzoic acid moiety were synthesized and studied as inhibitors of xanthine oxidase. This enzyme is a known target for allopurinol and febuxostat used in the treatment of hyperuricemia, gout, and other diseases. The synthesized compounds with different substituents in position 3 of the rhodanine ring showed in vitro inhibitory activities towards xanthine oxidase in a low micromolar concentration range. The 4-(furan-2-yl)benzoic acid derivative with a fragment of N-unsubstituted rhodanine was found to have the lowest IC50 value which does not depend on the presence of albumin or Tween-80 under the assay conditions. According to kinetic data, the rhodanine-based 4-(furan-2-yl)benzoic acid was a mixed-type inhibitor with the same affinity for the free enzyme and the enzyme-substrate complex. Molecular docking and molecular dynamic studies were performed to elucidate the binding mode of this compound in the active site of xanthine oxidase

30 June 2020 in Ukrainica Bioorganica Acta
Verified
Journal Article
Open access
MZMaryna Zhuravlova
Maryna Zhuravlova
NONataliya V Obernikhina
Nataliya V Obernikhina
SPStepan Pilyo
Stepan Pilyo
MKMaryna Kachaeva
Maryna Kachaeva
OKOleksiy Kachkovsky
Oleksiy Kachkovsky
VBVolodymyr S. Brovarets
Volodymyr S. Brovarets
The new model approach of interaction between the pharmacophores with bio-molecules, fragment-to-fragment, is presented. It is a new step of the molecular modeling and takes correctly into consideration not only the spatial complementarity of the interacted molecules but also the contribution of the stacking π-π-electron interaction and hydrogen bonds. As an example, the correct analysis of the interaction of the biological active phenyl-substituted 1,3-oxazoles with protein fragments is performed. It was shown that the length and energy of the hydrogen bond uniquely depend on the chemical constitution of both components in the created complex [Pharmacophore(Oxazole)-Biomolecule (H-X)]. The binding energy regularly decreases in the series X → O, S, NH (fragments of the corresponding biomolecules). It should be pointed out that introduction of the conjugated phenyl groups at positions 2 and 5 of oxazoles increase the stability of the possibly generated complex Pharmacophore-Biomolecule [Pharm-BioM] with fragments of the corresponding biomolecules along the core of oxazole by 0.2 and 0.5 kcal/mole. At the same time, modeling of the possibly generated complex [Pharm-BioM] by phenyl substituents at position 2 and 5 of 1,3-oxazole with phenylalanine as a fragment of protein molecules additionally stabilizes complex by 2.5 kcal/mole by π-stacking mechanism. It seems, the observed biological activity of the phenyl substituted 1,3-oxazole is rather connected with the possibility to generate the stable complex due to the formation of additional bonds with other fragments (conjugated phenyl core). The calculations give that such substituents do not cause spatial hindrances with the polypeptide chain.